FDA tar­gets prod­ucts false­ly claim­ing to treat Alzheimer’s dis­ease

De­vel­op­ing treat­ments for Alzheimer’s dis­ease has been no­to­ri­ous­ly dif­fi­cult, and now the FDA is crack­ing down on com­pa­nies fraud­u­lent­ly claim­ing that their di­etary sup­ple­ments can help treat, pre­vent or even cure the dis­ease.

The FDA on Mon­day re­leased 12 warn­ing let­ters and five ad­vi­so­ry let­ters to for­eign and do­mes­tic com­pa­nies that are il­le­gal­ly sell­ing more than 58 un­ap­proved new drugs and/or mis­brand­ed drugs that claim to pre­vent, treat or cure Alzheimer’s dis­ease and a num­ber of oth­er se­ri­ous dis­eases and health con­di­tions.

“To­day’s ac­tions are part of the FDA’s larg­er ef­fort to ad­dress the boom­ing growth of the di­etary sup­ple­ment in­dus­try through the im­ple­men­ta­tion of mod­ern reg­u­la­to­ry ini­tia­tives that will en­able the agency to pre­serve the bal­anced vi­sion of the Di­etary Sup­ple­ment Health and Ed­u­ca­tion Act (DSHEA), en­act­ed by Con­gress 25 years ago,” FDA Com­mis­sion­er Scott Got­tlieb said.

In­creased Reg­u­la­tion

Got­tlieb al­so out­lined sev­er­al ways in which the FDA is look­ing to move its reg­u­la­tion of di­etary sup­ple­ments for­ward, par­tic­u­lar­ly as in the 25 years since Con­gress passed the Di­etary Sup­ple­ment Health and Ed­u­ca­tion Act (DSHEA), the law that en­abled the FDA’s au­thor­i­ty to reg­u­late di­etary sup­ple­ments, the di­etary sup­ple­ment mar­ket has grown sig­nif­i­cant­ly.

“What was once a $4 bil­lion in­dus­try com­prised of about 4,000 unique prod­ucts, is now an in­dus­try worth more than $40 bil­lion, with more than 50,000 – and pos­si­bly as many as 80,000 or even more,” Got­tlieb said.

As far as up­com­ing changes, the FDA is ex­plor­ing new ways to com­mu­ni­cate more quick­ly when con­cerns arise that an in­gre­di­ent is un­law­ful and po­ten­tial­ly dan­ger­ous and should not be mar­ket­ed in di­etary sup­ple­ments. He al­so not­ed how the FDA is push­ing to­ward the sub­mis­sion of new di­etary in­gre­di­ent (NDI) no­ti­fi­ca­tions so the FDA could eval­u­ate the safe­ty of a new in­gre­di­ent be­fore it be­comes avail­able.

“We’re con­tin­u­ing to de­vel­op guid­ance for prepar­ing NDI no­ti­fi­ca­tions to en­sure FDA can thor­ough­ly re­view the safe­ty of these in­gre­di­ents. In con­junc­tion with this ef­fort, we’re plan­ning to up­date our com­pli­ance pol­i­cy re­gard­ing NDIs,” he said.

The agency is al­so plan­ning a pub­lic meet­ing this spring on the top­ic of re­spon­si­ble in­no­va­tion in the di­etary sup­ple­ment in­dus­try, open­ing the pos­si­bil­i­ty for a broad­er con­ver­sa­tion on whether cer­tain changes to the DSHEA might be help­ful.

For ex­am­ple, some stake­hold­ers have sug­gest­ed that the statute should be amend­ed to es­tab­lish av­enues for di­etary sup­ple­ment ex­clu­siv­i­ty and add a prod­uct list­ing re­quire­ment. A manda­to­ry list­ing re­quire­ment could al­so pro­vide sig­nif­i­cant ben­e­fits by im­prov­ing trans­paren­cy in the mar­ket­place and pro­mot­ing risk-based reg­u­la­tion, Got­tlieb said.

The Coun­cil for Re­spon­si­ble Nu­tri­tion, a trade as­so­ci­a­tion for the di­etary sup­ple­ment and func­tion­al food in­dus­try, ap­plaud­ed the moves by Got­tlieb and the FDA, and called on Con­gres­sion­al ap­pro­pri­a­tors to al­lo­cate to the FDA the fund­ing re­quired to ad­e­quate­ly po­lice sup­ple­ments and fol­low through on en­force­ment.


First pub­lished here and syn­di­cat­ed in part­ner­ship with RAPS. 

Im­age: Scott Got­tlieb. AP IM­AGES

Author

Zachary Brennan

managing editor, RAPS

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

There’s nothing quite like a big patent win when it comes to burnishing your prospects in the pipeline. And for Amgen, which seems to have rescued Enbrel for a run to 2029, the cheering section on Wall Street is now fixed on AMG 510 and a key rival.

And it didn’t take much data to do it. 

There was the first snapshot of a handful of patients, with a 50% response rate. Then came word that Amgen researchers are also tracking responses in different cancers, at least one in colorectal cancer and appendiceal too. 

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as CEO

→ Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences unit — was involved in the partnership that birthed the biotech spinout in the first place. As Cerevel’s first chief business officer, she is tasked with corporate development, program management as well as technical operations. 

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.